Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Dec 03, 2020 6:29pm
106 Views
Post# 32033728

RE:RE:250000 test/$18-$31M estimate was based on only 5 clients?

RE:RE:250000 test/$18-$31M estimate was based on only 5 clients?I like these three quotes as well, and remember it's based on initial interest, based again on only 5 clients not the 50+ we have now. Essentially ensuring our smooth operation and expansion, when including the offering, for 24 months.


"StageZero projects estimated revenue of US$18-$31 million from its COVID-19 testing within the twelve (12) month period from June 2020 to June 2021. This revenue projection is arrived at by multiplying the number of COVID-19 Tests for which StageZero received initial expressions of interest (being, 250,000 COVID-19 Tests from the first groups to initiate COVID-19 testing with StageZero) by prices-per-test in the range of US$75 per antibody COVID19 test to $150 per PCR COVID-19 test."

"The Company believes that based on management’s expected rate of revenue from operating activities, specifically COVID-19 testing revenue, the Company’s recent investments in increasing laboratory capacity and test processing, as well as the net proceeds in the Minimum Offering scenario of $4,360,032, plus the Company’s cash on hand of approximately $2,087,431 as of October 31, 2020, will be sufficient to cover all of the Company’s activities (i.e., all of the Company’s costs) during the period ending November 30, 2021 (being the period in which the proceeds of the Offering in the Minimum Offering scenario are expected to be used)."


"The Company expects to generate revenue from the execution of orders for diagnostic tests, initially focusing on COVID-19 Tests, but eventually including cancer screening tests as the healthcare industry normalizes. The Company expects this revenue to contribute funding toward operating activities. Anticipated revenue is expected to be sufficient to fund the Company’s expenditures for a further twelve (12) months."


Jonnyboy85 wrote: I'd love to know what SZLS estimates now, doubt they'll even bother with estimates at this point, better to lowball anyway, but I'd sure love even a low end updated estimate. A man can dream


Jonnyboy85 wrote: If I'm reading this right, the initial interest was based on the 5 clients specifically, and of course we have 50+ now. This blows all my estimates out of the water, potentially 10x higher than what I was expecting originally. Any thoughts? This is also pulled from the final prospectus dated Nov 26th 2020



"Upon initiating COVID-19 testing, the Company received initial customer interest for approximately 250,000 COVID-19 Tests from entities such as businesses and municipalities who wished to offer the COVID-19 Tests to their respective employees or citizens."


"During the first six weeks of COVID-19 testing, StageZero performed approximately 5,000 COVID-19 Tests. To the end of October, StageZero had performed approximately 13,000 COVID-19 Tests. The initial orders StageZero entered into for COVID-19 testing was with five (5) client groups; it is now performing tests for approximately fifty (50) client groups and adding more. New groups are being added on an ongoing basis. StageZero anticipates increasing demand for testing over the next several months and through the winter as planned COVID-19 testing commences according to the timetables set by these client groups. The projected growth in COVID-19 testing is occurring and is on pace with StageZero’s expectations with significant growth anticipated on a quarter over quarter basis in order to meet the projected revenue."




<< Previous
Bullboard Posts
Next >>